Hidalgo, Universidad Austral de Chile, Chile Mercedes Garca-Roche, Universidad de la Repblica, Uruguay Updates Copyright 2025 Seemann, Kersten, Bhler, Billenkamp, Meyer, Visscher, Huber, Most, Eder, Dnicke and Frahm
"Appropriate action should be initiated under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Drugs and Cosmetics Act, 1940 and Rules made thereunder against manufacturers, importers, marketers, or any other entities found in violation," the letter said
The standard treatment ladder goes something like this: start with joint supplements (glucosamine, chondroitin), add omega-3 fatty acids, move to NSAIDs when things get bad, then consider surgery or prescription pain management
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]